In this MEDtalk M.D. Professor of Oncology, Julie Brahmer from Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University presents data from KEYNOTE-024: Pembrolizumab double the 5-year OS rate for patients with metastatic, PD-L1-positive lung cancer vs ...

Johann de Bono presented the first results from the phase III study IPATential150 at this year’s ESMO Virtual Congress 2020. In IPATential150 ipatasertib is given in combination with abiraterone to patients with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) who had not previously been treated for mCRPC. 40-50% of mCRPC patients have loss ...

Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer. In this MEDtalk Professor Stephen Johnston, from the Royal Marsden Hospital NHS Foundation Trust, London, presents the new data presented at ESMO ...

Positive results with immunotherapy in combination with the chemotherapy nab paclitaxel in 1st line treatment of triple-negative and PD-L1-positive metastatic breast cancer. Disappointing results with the combination with paclitaxel suggest that the choice of chemotherapy is of great importance. Updated results from the phase III study IMpassion130, where atezolizumab was given in combination with nab-paclitaxel, ...

The KEYNOTE 590 trial examined first-line chemotherapy, with or without pembrolizumab, in patients with squamous cell carcinoma of the oesophagus, adenocarcinoma of the oesophagus, or Siewert type 1 gastro-oesophageal junction adenocarcinoma. In this MEDtalk Ken Kato, MD. PhD, National Cancer Center Hospital, Tokyo, presents the results of the KEYNOTE 590 ...

A planned interim analysis of the phase III study CROWN shows a significant improvement in progression-free survival (PFS) and a reduction in the incidence of brain metastases for lorlatinib compared to crizotinib in 1L treatment of patients with ALK positive stage IIIB/IV non-small cell lung cancer (NSCLC). The analysis was presented by Professor Benjamin Solomon ...

The results of the phase 3 CheckMate 9ER trial have provided a new first line treatment option for patients with metastatic kidney cancer. In this MEDtalk, Toni K. Choueiri , Director, The Lank Center for Genitourinary, Oncology, Dana-Farber Cancer Institute, and professor of Harvard Medical School, Boston, USA, presents the data for the combinations therapy of ...